Trained Circulating Monocytes in Atherosclerosis: Ex Vivo Model Approach - PubMed (original) (raw)

Trained Circulating Monocytes in Atherosclerosis: Ex Vivo Model Approach

Nikita G Nikiforov et al. Front Pharmacol. 2019.

Abstract

Inflammation is one of the key processes in the pathogenesis of atherosclerosis. Numerous studies are focused on the local inflammatory processes associated with atherosclerotic plaque initiation and progression. However, changes in the activation state of circulating monocytes, the main components of the innate immunity, may precede the local events. In this article, we discuss tolerance, which results in decreased ability of monocytes to be activated by pathogens and other stimuli, and training, the ability of monocyte to potentiate the response to pathological stimuli, and their relation to atherosclerosis. We also present previously unpublished results of the experiments that our group performed with monocytes/macrophages isolated from atherosclerosis patients. Our data allow assuming the existence of relationship between the formation of monocyte training and the degree of atherosclerosis progression. The suppression of trained immunity ex vivo seems to be a perspective model for searching anti-atherogenic drugs.

Keywords: activation; atherosclerosis; inflammation; intima; lipoproteins; monocyte; tolerance; training.

PubMed Disclaimer

Figures

Figure 1

Figure 1

TNF secretion and expression level by human monocytes under LPS stimulation correlates directly with IMT and inversely with HDL cholesterol. (A and B) Correlation between TNF expression (A) or secretion (B) level by LPS-stimulated monocytes and IMT. (C and D) Correlation between the abilities of LPS-stimulated and non-stimulated monocytes express (C) or produce (D) TNF. (E and F) Correlation between TNF expression (E) or secretion (F) level by LPS-stimulated monocytes and HDL cholesterol. Each point on graphs corresponds to one patient. PPC, Pearson correlation coefficient.

References

    1. Bauer M., Weis S., Netea M. G., Wetzker R. (2018). Remembering pathogen dose: long-term adaptation in innate immunity. Trends Immunol. 39 (6), 438–445. 10.1016/j.it.2018.04.001 - DOI - PubMed
    1. Bekkering S., van den Munckhof I., Nielen T., Lamfers E., Dinarello C., Rutten J., et al. (2016). Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo. Atherosclerosis 254, 228–236. 10.1016/j.atherosclerosis.2016.10.019 - DOI - PubMed
    1. Bentzon J. F., Otsuka F., Virmani R., Falk E. (2014). Mechanisms of plaque formation and rupture. Circ. Res. 114 (12), 1852–1866. 10.1161/CIRCRESAHA.114.302721 - DOI - PubMed
    1. Biswas S. K., Lopez-Collazo E. (2009). Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immumol. 30 (10), 475–487. 10.1016/j.it.2009.07.009 - DOI - PubMed
    1. Cheng S. C., Quintin J., Cramer R. A., Shepardson K. M., Saeed S., Kumar V., et al. (2014). mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345 (6204), 1250684. 10.1126/science.1250684 - DOI - PMC - PubMed

LinkOut - more resources